Artivion/$AORT
1D1W1MYTD1Y5YMAX
Capital at risk
About Artivion
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
- Ticker
- $AORT
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 1,800
- Headquarters
- Kennesaw, United States
- Website
- artivion.com
Artivion Metrics
BasicAdvanced
$1.1B
-
-$0.07
1.25
-
Price and volume
Market cap
$1.1B
Beta
1.25
52-week high
$48.25
52-week low
$19.16
Average daily volume
679K
Financial strength
Current ratio
3.473
Quick ratio
1.759
Long term debt to equity
0.902
Total debt to equity
0.916
Interest coverage (TTM)
1.38%
Profitability
EBITDA (TTM)
63.715
Gross margin (TTM)
64.37%
Net profit margin (TTM)
-0.67%
Operating margin (TTM)
8.30%
Effective tax rate (TTM)
241.74%
Revenue per employee (TTM)
$260,000
Management effectiveness
Return on assets (TTM)
2.56%
Return on equity (TTM)
-0.73%
Valuation
Price to revenue (TTM)
2.338
Price to book
2.52
Price to tangible book (TTM)
-8.74
Price to free cash flow (TTM)
-64.236
Free cash flow yield (TTM)
-1.56%
Free cash flow per share (TTM)
-0.359
Growth
Revenue change (TTM)
16.40%
Earnings per share change (TTM)
-84.21%
3-year revenue growth (CAGR)
12.77%
10-year revenue growth (CAGR)
10.96%
3-year earnings per share growth (CAGR)
-54.37%
10-year earnings per share growth (CAGR)
-14.29%
What the Analysts think about Artivion
Analyst ratings (Buy, Hold, Sell) for Artivion stock.
Analyst projections of the future price of Artivion stock.
Bulls say / Bears say
Artivion delivered strong Q2 2026 momentum, with revenue up 11% year over year to $125.8 million, constant-currency revenue up 9%, and adjusted EBITDA up 7%. Management maintained a 2026 revenue outlook of $480 million to $496 million and adjusted EBITDA guidance of $92 million to $99 million. (Artivion Q2 2026 results)
The FDA’s June 2026 PMA approval for AMDS expands its U.S. commercial opportunity by removing the institutional-review-board approval requirement associated with the prior humanitarian-device exemption. The approval covers acute DeBakey Type I dissections with malperfusion, which Artivion estimates represent approximately 60% of cases in that category. (Artivion FDA announcement)
The April FDA approval of the NEXUS Aortic Arch System and Artivion’s May completion of the Endospan acquisition broaden the company’s aortic-arch portfolio and add another commercial growth platform. Q2 results also showed aortic-stent-graft revenue up 16% and On-X revenue up 19% year over year, supporting the strategic rationale for the expansion. (SEC Form 10-Q)
Artivion remained unprofitable on a GAAP basis in Q2 2026, posting a $13.5 million net loss and an $8.4 million operating loss. General, administrative, and marketing expenses rose 38%, partly due to Endospan transaction costs and higher sales, marketing, and stock-compensation spending. (SEC Form 10-Q)
The Endospan acquisition materially increased financial leverage: total principal debt rose to $370 million at June 30, 2026 from $220 million at year-end 2025, with the new $150 million term loan carrying an 8.40% stated rate. Artivion also disclosed $143.7 million of anticipated interest payments on its term and revolving facilities. (SEC Form 10-Q)
Core margin and product-mix execution remain uneven: Q2 gross margin fell to 64% from 65% a year earlier, while product costs increased 20%. Surgical-sealant revenue was flat year over year and declined 2% on a constant-currency basis, indicating that growth is concentrated in select product lines. (SEC Form 10-Q)
Data summarised monthly by Lightyear AI. Last updated on 10 Sept 2026.
Artivion Financial Performance
Revenues and expenses
Artivion Earnings Performance
Company profitability
Upcoming events
No upcoming events
Artivion News
AllArticlesVideos
Funds containing Artivion
AllUSDGBPEUR
Fund name | Fund size | $AORT weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.07% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.04% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.